serum ceacam1 correlates with disease progression and survival in malignant melanoma patients血清ceacam1与恶性黑色素瘤患者的疾病进展和生存.pdf

Hindawi Publishing Corporation Clinical and Developmental Immunology Volume 2012, Article ID 290536, 8 pages doi:10.1155/2012/290536 Clinical Study Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients Sapoznik Sivan,1 Faranesh Suzan,2 Ortenberg Rona,1, 3 Hamburger Tamar,2 Barak Vivian,2 Peretz Tamar,2 Schachter Jacob,1 Markel Gal,1, 3, 4 and Lotem Michal2 1 The Ella Institute for Treatment and Research of Melanoma and Skin Cancer, The Sheba Cancer Research Center, The chaim Sheba Medical Center, Tel Hashomer 52621, Israel 2 Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel 3 Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 4 Talpiot Medical Leadership Program, The chaim Sheba Medical Center, Tel Hashomer, Israel Correspondence should be addressed to Markel Gal, markel@post.tau.ac.il and Lotem Michal, mlotem@ Received 30 June 2011; Revised 26 September 2011; Accepted 28 September 2011 Academic Editor: Tetsuya Nakatsura Copyright © 2012 Sapoznik Sivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The search for melanoma biomarkers is crucial, as the incidence of melanoma continues to rise. We have previously demonstrated that serum CEACAM1 (sCEACAM1) is secreted from melanoma cells and correlates with disease progression in metastatic melanoma patients. Here, we have used a different cohort of melanoma patients with regional or metastatic disease (N = 49), treated with autologous vaccination. By